Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project-A combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS)

The American Journal of Cardiology

Volumn 76, Issue 12, 1995, Pages 899-905

  The PPP Project Investigators, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; PRAVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTICLE; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DOUBLE BLIND PROCEDURE; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; META ANALYSIS; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; FEMALE; HUMANS; MALE; META-ANALYSIS; MIDDLE AGED; MULTICENTER STUDIES; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0029410625     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)80259-8     Document Type: Article

References (30)

1. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence
2. Cholesterol-lowering trial results in their epidemiological context
3. The value of lowering cholesterol after myocardial infarction
4. The Lipid Research Clinics Coronary Primary Prevention Trial Results
5. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
6. Does cholesterol lowering reduce total mortality?
7. Should there be a moratorium on the use of cholesterol lowering drugs?
8. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials
9. Cholesterol and total mortality: need for larger trials [letter]
10. Clinical implications of new drugs for lowering plasma cholesterol concentrations
11. Long-term experience with pravastatin in clinical research trials
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
13. Pravastatin, Lipids and Atherosclerosis in the Carotid Arteries (PLAC II)
14. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)
15. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens
16. Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris
17. Baseline Characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol
18. Screening experience and baseline characteristics in the West of Scotland coronary prevention study
19. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
20. Explanatory and pragmatic estimates of the treatment effect when deviations from allocated treatment occur
21. Proportional hazards tests and diagnostics based on weighted residuals
22. Statistical aspects of the analysis of data from retrospective studies of disease.
23. The analysis of multiple end points in clinical trials
24. Cholesterol and mortality: 30 years of follow-up from the Framingham study
25. Serum cholesterol, blood pressure and mortality; implications from a cohort of 361,662 men
26. Cholesterol lowering and mortality: the importance of considering initial level of risk.
27. Assessing possible hazards of reducing serum cholesterol
28. Pravastatin, lipids, and major coronary events